logo image
search icon
Clinical Oncology Next Generation Sequencing Market

Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Application Type (Screening, Companion Diagnostics, and Other Diagnostics), By End User (Hospitals, Clinics, and Laboratories), By Technology Type (Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing & Resequencing), By Workflow Type (NGS Pre-Sequencing, NGS Sequencing, and NGS Data Analysis), By Region, And By Segment Forecasts, 2023-2031.

Report ID : 2249 | Published : 2023-12-04 | Pages: 179 | Format: PDF/EXCEL

Clinical Oncology Next Generation Sequencing Market Size is predicted to reach record a 15.86% CAGR during the forecast period for 2023-2031.

Clinical Oncology Next Generation Sequencing Market

Next-generation sequencing (NGS) in clinical oncology refers to the use of advanced genomic sequencing technology to analyze cancer-related genes in patients. NGS enables the rapid and thorough study of a patient's tumour DNA, RNA, or epigenetic alterations, providing crucial information for cancer diagnosis, prognosis, and therapy planning. The primary drivers driving clinical oncology next-generation Sequencing (NGS) market growth include increasing technological advancements, rivalry among competitors, rising healthcare spending, and an increase in cancer prevalence. Furthermore, increasing R&D activities to invent solutions is likely to propel market development in the coming years.

However, the global clinical oncology next-generation sequencing (NGS) industry has been crucially affected by the COVID-19 pandemic, affecting several elements, including research, diagnosis, treatments, and market dynamics. Many cancer-related research activities and clinical trials were either halted or delayed as a result of lockdowns and limitations, affecting the creation of genomic data for NGS analysis.

Competitive Landscape

Some Major Key Players In The Clinical Oncology Next Generation Sequencing Market:

  • Illumina Inc.
  • Thermo Fisher Scientific
  • Hoffmann-La Roche Ltd.
  • Agilent Technologies
  • Myriad Genetics
  • Perkin Elmer
  • Caris Life Sciences
  • Partek, Inc.
  • Eurofins Scientific
  • Qiagen N.V.
  • Foundation Medicine
  • Pacific Bioscience
  • Oxford Nanopore Technologies Ltd.
  • Paradigm Diagnostics
  • Beijing Genomics Institute (BGI)
  • Takara Bio, Inc
  • Creative-Biolabs
  • Others

Market Segmentation:

The Global Clinical Oncology Next Generation Sequencing Market is segmented on the basis of technology type, end-user, application, and workflow type. The technology type segment is divided as Whole Exome Sequencing, Whole Genome Sequencing, Targeted Sequencing and re-sequencing. The end-user segment includes Hospitals, Clinics, and Laboratories. By application, the market is segmented into Screening, Companion Diagnostics, and other Diagnostics. The workflow segment includes NGS Pre-Sequencing, NGS Sequencing, and NGS Data Analysis.

Based On Technology, The Targeted Sequencing And Re-Sequencing Segment Is A Major Contributor To The Global Clinical Oncology Next-Generation Sequencing Market. 

The targeted sequencing and re-sequencing category is expected to hold a major share of the global clinical oncology next-generation sequencing market in 2022. This is due to the numerous advantages connected with this technique, such as reduced time, cost, and quantity of data analyzed during tumour sample sequencing. Furthermore, because tailored panels are effective at detecting malignant tumours, their clinical utility grows. Therapeutic studies have shown that tailored panels have a high therapeutic value, making them a preferred choice for approximately 64% of cancer patients. According to a study published in the journal JCO Precision Oncology in September 2020, NGS panels are therapeutically useful in 64% of cancer cases.

The Screening Segment Witnessed Growth At A Rapid Rate.

The screening segment is projected to grow at a rapid rate in the global clinical oncology next-generation sequencing market owing to the widespread use of NGS in cancer screening programs around the world. NGS-based testing is now widely regarded as the most effective method for finding genetic changes targeted for clinical benefit in cancer patients. This method allows clinicians to analyze several gene changes at the same time.

In The Region, The North American Clinical Oncology Next Generation Sequencing Market Holds A Significant Revenue Share.

The North American Clinical Oncology Next Generation Sequencing Market is expected to record the maximum market share in terms of revenue in the near future owing to the efforts implemented by regulatory agencies to enhance cancer screening diagnosis in the U.S., rising R&D investment and the presence of a significant market in the region. Moreover, due to regulatory initiatives to increase cancer screening diagnosis in the United States, increased R&D expenditure, and the presence of important competitors in the area. The region's key players are working on technical developments in order to improve their market position and give the best solutions. Because of lower sequencing costs, favourable government policies, increased R&D investments, and competitive pricing by important companies, the Asia Pacific area is likely to grow at a rapid rate. The cost of sequencing has dropped dramatically in China.

Recent Developments:

  • In July 2023, Illumina Inc. and Pillar Biosciences Inc. have formed a strategic relationship to offer Pillar's range of oncology tests worldwide as part of Illumina's collection of oncology solutions. The agreement will lead to an unparalleled provision of supplementary next-generation sequencing solutions that will improve the efficiency, precision, and cost-effectiveness of oncology testing through advanced sequencing techniques, thereby enhancing patient access to personalized cancer treatment options.
  • In May 2023, Thermo Fisher Scientific and Pfizer joined forces to enhance the availability of advanced genetic testing for breast and lung cancer patients in more than 30 countries across Africa, the Middle East, Latin America, and Asia. These regions previously faced limitations or lack of access to state-of-the-art genomic testing.

Clinical Oncology Next Generation Sequencing Market Report Scope

Report Attribute

Specifications

Growth Rate CAGR

CAGR of 15.86 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Application Type, By End User, By Technology Type, By Workflow Type

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Competitive Landscape

Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche Ltd., Myriad Genetics, Perkin Elmer, Caris Life Sciences, Partek, Inc., Eurofins Scientific, and Qiagen N.V., Foundation Medicine, Pacific Bioscience, Oxford Nanopore Technologies Ltd., Paradigm Diagnostics, Beijing Genomics Institute (BGI), Takara Bio, Inc, Creative-Biolabs, and Others

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Clinical Oncology Next Generation Sequencing Market Snapshot

Chapter 4. Global Clinical Oncology Next Generation Sequencing Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Application Type Estimates & Trend Analysis

5.1. By Application Type, & Market Share, 2020 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Application Type:

5.2.1. Screening

5.2.2. Companion Diagnostics

5.2.3. Other Diagnostics

Chapter 6. Market Segmentation 2: By End User Estimates & Trend Analysis

6.1. By End User & Market Share, 2020 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End User:

6.2.1. Hospitals

6.2.2. Clinics

6.2.3. Laboratorie

Chapter 7. Market Segmentation 3: By Technology Type Estimates & Trend Analysis

7.1. By Technology Type & Market Share, 2020 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Technology Type:

7.2.1. Whole Genome Sequencing

7.2.2. Whole Exome Sequencing

7.2.3. Targeted Sequencing & Resequencing

Chapter 8. Market Segmentation 4: By Workflow Type Estimates & Trend Analysis

8.1. By Workflow Type & Market Share, 2020 & 2031

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Workflow Type:

8.2.2. NGS Pre-Sequencing

8.2.3. NGS Sequencing

8.2.4. NGS Data Analysis

Chapter 9. Clinical Oncology Next Generation Sequencing Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America

9.1.1. North America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) estimates and forecasts By Application Type, 2019-2031

9.1.2. North America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) estimates and forecasts By End User, 2019-2031

9.1.3. North America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) estimates and forecasts By Technology Type, 2019-2031

9.1.4. North America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) estimates and forecasts By Workflow Type, 2019-2031

9.1.5. North America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

9.2. Europe

9.2.1. Europe Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Application Type, 2019-2031

9.2.2. Europe Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By End User, 2019-2031

9.2.3. Europe Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Technology Type, 2019-2031

9.2.4. Europe Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Workflow Type, 2019-2031

9.2.5. Europe Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) by country, 2019-2031

9.3. Asia Pacific

9.3.1. Asia Pacific Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Application Type, 2019-2031

9.3.2. Asia Pacific Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By End User, 2019-2031

9.3.3. Asia Pacific Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Technology Type, 2019-2031

9.3.4. Asia Pacific Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Workflow Type, 2019-2031

9.3.5. Asia Pacific Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) by country, 2019-2031

9.4. Latin America

9.4.1. Latin America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Application Type, (US$ Million) 2019-2031

9.4.2. Latin America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By End User, (US$ Million) 2019-2031

9.4.3. Latin America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Technology Type, (US$ Million) 2019-2031

9.4.4. Latin America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Workflow Type, (US$ Million) 2019-2031

9.4.5. Latin America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) by country, 2019-2031

9.5. Middle East & Africa

9.5.1. Middle East & Africa Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Application Type, (US$ Million) 2019-2031

9.5.2. Middle East & Africa Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By End User, (US$ Million) 2019-2031

9.5.3. Middle East & Africa Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Technology Type, (US$ Million) 2019-2031

9.5.4. Middle East & Africa Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Workflow Type, (US$ Million) 2019-2031

9.5.5. Middle East & Africa Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) by country, 2019-2031

Chapter 10. Competitive Landscape

10.1. Major Mergers and Acquisitions/Strategic Alliances

10.2. Company Profiles

10.2.1. llumina Inc.,

10.2.2. Thermo Fisher Scientific,

10.2.3. F. Hoffmann-La Roche Ltd.,

10.2.4. Agilent Technologies,

10.2.5. Myriad Genetics,

10.2.6. Perkin Elmer,

10.2.7. Caris Life Sciences,

10.2.8. Partek, Inc.,

10.2.9. Eurofins Scientific,

10.2.10. Qiagen N.V. 

Segmentation of Global Clinical Oncology Next Generation Sequencing Market-

Clinical Oncology Next Generation Sequencing Market By Technology Type-

  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Re-sequencing

Clinical Oncology Next Generation Sequencing Market Seg

Clinical Oncology Next Generation Sequencing Market By End-User-

  • Hospitals
  • Clinics
  • Laboratories

Clinical Oncology Next Generation Sequencing Market By Application-

  • Screening
  • Companion Diagnostics
  • Other Diagnostics

Clinical Oncology Next Generation Sequencing Market By Workflow Type-

  • NGS Pre-Sequencing
  • NGS Sequencing
  • NGS Data Analysis

Clinical Oncology Next Generation Sequencing Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

What is the Clinical Oncology Next Generation Sequencing Market Growth?

Oxford Nanopore Technologies Ltd., Paradigm Diagnostics, Beijing Genomics Institute (BGI), Takara Bio, Inc, Creative-Biolabs, and Others

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach